v3.26.1
The company - 2014 Novo Nordisk A/S monalizumab agreement (Details)
€ / shares in Units, € in Thousands, $ in Millions
1 Months Ended 12 Months Ended
Feb. 05, 2014
EUR (€)
€ / shares
shares
Apr. 30, 2016
EUR (€)
Dec. 31, 2025
EUR (€)
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
EUR (€)
Dec. 31, 2018
EUR (€)
Dec. 31, 2018
USD ($)
Disclosure of disaggregation of revenue from contracts with customers [line items]                
Purchase of intangible assets     € 0 € 0 € 2,000      
Total financial liabilities     22,571 30,995 39,893 € 42,251    
Intangible assets     0 0 € 416 € 1,553    
2014 Novo Nordisk A/S monalizumab agreement                
Disclosure of disaggregation of revenue from contracts with customers [line items]                
Purchase of intangible assets € 2,000 € 6,500            
Shares issued for the acquisition of C5aR intangible asset (in shares) | shares 600,000              
Share issued, price per share (in EUR per share) | € / shares € 8.33              
Issue shares for licenses € 5,000              
Maximum potential regulatory milestones and single-digit tiered royalties on sale of products 20,000              
Total financial liabilities             € 13,100 $ 15.0
Potential additional milestone payments 0              
Intangible assets € 7,000   € 0 € 0